SLDB Cash-Secured Put Strategy
SLDB (Solid Biosciences Inc.), in the Healthcare sector, (Biotechnology industry), listed on NASDAQ.
Solid Biosciences Inc. engages in developing therapies for duchenne muscular dystrophy in the United States. The company's lead product candidate is SGT-001, a gene transfer candidate, which is in a Phase I/II clinical trial to drive functional dystrophin protein expression in patients' muscles; and SGT-003, a ext-generation gene transfer candidate for the treatment of duchenne muscular dystrophy. It also engages in developing of platform technologies, including dual gene expression, a technology for packaging multiple transgenes into one vector, as well as novel capsids. The company has collaboration and license agreement with Ultragenyx Pharmaceutical Inc. to develop and commercialize new gene therapies for Duchenne Muscular Dystrophy. Solid Biosciences Inc. was incorporated in 2013 and is headquartered in Cambridge, Massachusetts.
SLDB (Solid Biosciences Inc.) trades in the Healthcare sector, specifically Biotechnology, with a market capitalization of approximately $575.0M, a beta of 2.47 versus the broader market, a 52-week range of 2.41-8.866, average daily share volume of 1.3M, a public-listing history dating back to 2018, approximately 100 full-time employees. These structural characteristics shape how SLDB stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.
A beta of 2.47 indicates SLDB has historically moved more than the broader market, amplifying both the directional payoff and the realized volatility relative to an index-equivalent position.
What is a cash-secured put on SLDB?
A cash-secured put sells an out-of-the-money put while holding cash equal to the strike-times-100 obligation, keeping the premium when the underlying stays above the strike.
Current SLDB snapshot
As of May 15, 2026, spot at $6.82, ATM IV 187.70%, IV rank 38.63%, expected move 53.81%. The cash-secured put on SLDB below is built from the same end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 34-day expiry.
Why this cash-secured put structure on SLDB specifically: SLDB IV at 187.70% is mid-range versus its 1-year history, so the credit collected on a SLDB cash-secured put sits in line with its long-run distribution, with a market-implied 1-standard-deviation move of approximately 53.81% (roughly $3.67 on the underlying). The 34-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated SLDB expiries trade a higher absolute premium for lower per-day decay. Position sizing on SLDB should anchor to the underlying notional of $6.82 per share and to the trader's directional view on SLDB stock.
SLDB cash-secured put setup
The SLDB cash-secured put below is built from the end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With SLDB near $6.82, the first option leg uses a $6.48 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed SLDB chain at a 34-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 SLDB shares for the stock leg in covered calls and collars).
| Action | Type | Strike / Basis | Premium (est) |
|---|---|---|---|
| Sell 1 | Put | $6.48 | N/A |
SLDB cash-secured put risk and reward
- Net Premium / Debit
- N/A
- Max Profit (per contract)
- Unbounded
- Max Loss (per contract)
- Unbounded
- Breakeven(s)
- None on modeled curve
- Risk / Reward Ratio
- N/A
Max profit equals premium times 100; max loss equals strike minus premium times 100 (at zero, assuming assignment). Breakeven is strike minus premium.
SLDB cash-secured put payoff curve
Modeled P&L at expiration across a range of underlying prices for the cash-secured put on SLDB. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.
When traders use cash-secured put on SLDB
Cash-secured puts on SLDB earn premium while a trader waits to acquire SLDB stock at a target strike below the current quote; most attractive when IV is rich and the trader is comfortable owning SLDB.
SLDB thesis for this cash-secured put
The market-implied 1-standard-deviation range for SLDB extends from approximately $3.15 on the downside to $10.49 on the upside. A SLDB cash-secured put lets a trader earn premium while waiting to acquire SLDB at the strike price; the strategy is most attractive when the trader is comfortable holding the underlying at that level and IV is rich enough to compensate for the assignment risk. Current SLDB IV rank near 38.63% is mid-range against its 1-year distribution, so the IV signal is neutral; the cash-secured put thesis on SLDB should anchor more to the directional view and the expected-move geometry. As a Healthcare name, SLDB options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to SLDB-specific events.
SLDB cash-secured put positions are structurally neutral to slightly bullish; the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. SLDB positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move SLDB alongside the broader basket even when SLDB-specific fundamentals are unchanged. Short-premium structures like a cash-secured put on SLDB carry tail risk when realized volatility exceeds the implied move; review historical SLDB earnings reactions and macro stress periods before sizing. Always rebuild the position from current SLDB chain quotes before placing a trade.
Frequently asked questions
- What is a cash-secured put on SLDB?
- A cash-secured put on SLDB is the cash-secured put strategy applied to SLDB (stock). The strategy is structurally neutral to slightly bullish: A cash-secured put sells an out-of-the-money put while holding cash equal to the strike-times-100 obligation, keeping the premium when the underlying stays above the strike. With SLDB stock trading near $6.82, the strikes shown on this page are snapped to the nearest listed SLDB chain strike and the premiums come straight from the end-of-day bid/ask midpoint.
- How are SLDB cash-secured put max profit and max loss calculated?
- Max profit equals premium times 100; max loss equals strike minus premium times 100 (at zero, assuming assignment). Breakeven is strike minus premium. For the SLDB cash-secured put priced from the end-of-day chain at a 30-day expiry (ATM IV 187.70%), the computed maximum profit is unbounded per contract and the computed maximum loss is unbounded per contract. Live intraday quotes will differ as the chain moves through the trading session.
- What is the breakeven for a SLDB cash-secured put?
- The breakeven for the SLDB cash-secured put priced on this page is no defined breakeven on the modeled curve at expiration, derived from end-of-day chain premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The current SLDB market-implied 1-standard-deviation expected move is approximately 53.81%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
- When should you consider a cash-secured put on SLDB?
- Cash-secured puts on SLDB earn premium while a trader waits to acquire SLDB stock at a target strike below the current quote; most attractive when IV is rich and the trader is comfortable owning SLDB.
- How does current SLDB implied volatility affect this cash-secured put?
- SLDB ATM IV is at 187.70% with IV rank near 38.63%, which is mid-range against its 1-year history. Strategy selection depends more on directional thesis and expected move than on a strong IV signal.